References
- Thorogood M., Vessey M. P. Trends in use of oral contraceptives in Britain. Br. J. Fain. Plann. 1990; 16: 41–53
- Scowen E. E. Oral contraceptives containing oestrogen. Br. Med. J. 1969; 2: 744
- RCGP Oral Contraception Study. Mortality among oral contraceptive users. Lancet 1977; 2: 727–30
- Vessey M. P., McPherson K., Johnson B. Mortality among women participating in the Oxford/Family Planning Association Contraceptive Study. Lancet 1977; 2: 731–4
- Upton G. V. The phasic approach of oral contraception: the triphasic concept and its clinical applications. Int. J. Fertil. 1983; 28: 121–40
- Fotherby K. Oral contraceptives and lipids. Br. Med. J. 1989; 298: 1049–50
- Fitzgerald O., Feichtinger W., Spona J., Elstein M., Lüdicke F., Müller U., Williams C. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv. Contracept. 1994; 10: 5–18
- Lähteenmäki P., Moorrees M., De Prest J., Elomaa K., Rolland R., Brosens I. Extension of the pill-free period by three days in oral contraceptive users. Adv. Contracept. 1995; 11: 37–8
- Hoppe G. Gestodene, an innovative progestogen. Contraception 1988; 37: 493–501
- Rabe T., Runnebaum B., Kohlmeier M., Har-enberg J., Weicker H. Clinical and metabolic effects of gestodene and levonorgestrel. Int. J. Fertil. 1987; 32: 29–44
- Andrade R. P. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinylestradiol). Int. J. Fertil. 1989; 34(Suppl)22–30
- Data on file
- Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 |J.g oestrogen. Contraception 1992; 46: 477–88